The long term effect of (3 blockers and the influence of intrinsic sympathomimetic activity on respiratory function were assessed in patients with chronic stable angina pectoris randomised to receive treatment with propranolol (n= 21) or pindolol (n= 19) for one year. Forced expiratory volume in one second (FEVI) had fallen by a mean of 240 ml after one year (p<0-001) in those treated with propranolol compared with 120 ml in those treated with pindolol (p<O05). The difference between the groups was significant (p<0-01). Vital capacity fell significantly only in those treated with propranolol (p<0-05 at one year). In those in whom the basal ratio of FEVy to forced vital capacity was low (<70%) propranolol, but not pindolol, caused a significant (p<O0OS) fall in FEV, throughout treatment.
Introduction
Blockers may have a deleterious effect on respiratory function owing to blockade of the adrenoceptors in the lung, which are responsible for bronchomotor tone; this results in appreciable bronchoconstriction in susceptible subjects, such as those with chronic obstructive airways disease, in whom the use of ( Although propranolol caused a progressive and highly significant reduction in FEV1 (table III) , it is not clear whether a reduction of 240 ml in FEV1 (at 52 weeks) is clinically important as none of the patients reported increasing breathlessness or wheeze with this drug. It is also possible that the deterioration in respiratory function might progress beyond one year in a cumulative fashion, resulting in a worsening of symptoms. This effect of long term oral administration of propranolol in patients with chronic obstructive airways disease would probably result in symptomatic deterioration in pulmonary function in patients who did not initially have symptoms. Though the drug did not cause a rapid and dramatic clinical exacerbation in our patients, it did cause a definite and sustained increase in airways obstruction compared with pindolol.
The significantly greater deterioration in variables of respiratory function presumed to reflect changes in large airway calibre that we found with propranolol compared with an agent with intrinsic sympathomimetic activity has been mentioned previously. 22 Patakas et al, however, when studying respiratory function after single oral doses of propranolol (40 mg) and pindolol (2 5 mg) in asthmatic patients, confirmed that propranolol has a bronchoconstrictive effect on large and small airways but found that pindolol, although it did not have a significant effect on large airway calibre, caused a significant bronchoconstriction of the small airways.23 They suggested that pindolol remains potentially dangerous in asthmatic patients because of this effect on small airways. Most previous studies have examined the effect of single oral or intravenous doses of 13 blockers, usually in patients with reversible airways obstruction. Studies evaluating the effect of 13 blockers on respiratory function in patients receiving -long term treatment for hypertension or angina pectoris are rare. Several studies have examined exclusively non-selective agents without intrinsic sympathomimetic activity. Two such studies of intravenous propranolol found an increase in airways resistance after only a few minutes.' 24 The consensus is that these agents result in a predictable deterioration in respiratory function in the short term.252
Several studies have evaluated the role of intrinsic sympathomimetic activity on respiratory function. Benson et al carried out an acute study in 12 asthmatic subjects who received placebo, propranolol (100 mg), pindolol (5 mg), acebutolol (300 mg), and atenolol (100 mg) and showed that propranolol caused the greatest reduction in FEV1.27 Others have confirmed the benefit of intrinsic sympathomimetic activity.28 One disadvantage of agents with intrinsic sympathomimetic activity compared with cardioselective drugs was shown in a study of the effect of metoprolol and acebutolol on eight asthmatic subjects.2" FEV, and peak expiratory flow rate were reduced significantly by both drugs, but after an infusion of terbutaline a dose dependent increase in the two variables occurred, although the increase was partly inhibited by acebutolol compared with atenolol. Thus if airways obstruction does occur it is less likely to be reversed by a 12 agonist if the 13 blocker is not relatively PI3 selective.
Thus there is agreement that non-selective agents without intrinsic sympathomimetic activity cause potentially harmful changes in respiratory function in patients with asthma and possibly also in those with irreversible chronic obstructive airways disease and even healthy subjects. Cardioselectivity tends to reduce the bronchoconstrictive effect, as does intrinsic sympathomimetic activity.
The available evidence suggests that no 1 blocker is entirely safe in patients with chronic obstructive airways disease. If possible an alternative drug should first be considered. Bronchoconstriction after administration of a 13 blocker is most pronounced in those with reversible bronchial obstruction. 13 Blockers with intrinsic sympathomimetic activity or cardioselectivity have a less pronounced effect on pulmonary function and so should be preferred in cases in which a 13 blocker is thought desirable despite the presence of respiratory impairment.
Ideally, it would be advantageous to develop a 13 blocker with no adverse effects on respiratory function-that is, a completely cardioselective agent. This, however, would not be possible as it has been established that 0 1 and 02 receptors are not completely separated in different organs, as was postulated by Lands et al.to
